Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 4,127 matching trials from the local directory fallback.

Filters: Chicago, Illinois Clear all

Conditions: Intracranial Aneurysm
Interventions: Artisse™ Intrasaccular Device; Device
Lead sponsor: Medtronic Neurovascular Clinical Affairs; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 25
States / cities: Los Angeles, California • Englewood, Colorado • New Haven, Connecticut + 21 more

Conditions: Environmental Exposure, PFAS Exposure
Interventions: Placebo, Streptococcus salivarius 46-SL1; Dietary Supplement
Lead sponsor: Cambiotics ApS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Oropharyngeal Carcinoma (OPC)
Interventions: CRB-701, Cetuximab (EGFR inhibitor), Docetaxel, capcitabine; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more

Conditions: Obesity, Overweight
Interventions: Eloralintide, Macupatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more

Conditions: Advanced Cancer, End of Life
Interventions: ROCKS, Usual Care; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: ARGX-119 IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more

Conditions: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
Interventions: Nucresiran, Vutrisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms by Site, Rectal Diseases
Interventions: Bevacizumab, Chemotherapy, PF-08634404; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 254
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more

Conditions: Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 226
States / cities: Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Placebo, Retatrutide, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 141
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more

Conditions: COPD
Interventions: Education (counselor-led), Education (self-guided), Inhaler Training, Physical Activity; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease
Interventions: KarX-EC, KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Fullerton, California • Irvine, California • Los Angeles, California + 28 more

Conditions: Rheumatoid Arthritis
Interventions: Lutikizumab, Placebo, Ravagalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 49
States / cities: Peoria, Arizona • Jonesboro, Arkansas • Beverly Hills, California + 42 more

Conditions: Sickle Cell Disease Vaso-occlusive Crisis
Interventions: CSL889, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more

Conditions: Injection Complication, Injection Fear, Injection Pain Prevention
Interventions: Cold Saline Spray, Ethyl Chloride; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Sickle Cell Disease
Interventions: CBT w/o Health Coach ( self-guided), CBT+ Health coach, Usual Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 16 Years to 39 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Mobile, Alabama • Los Angeles, California • Hartford, Connecticut + 10 more

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: AZD0120; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more

Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions: Active Comparator, Cytoreductive Nephrectomy; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 387
States / cities: Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more

Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 334
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more

Conditions: Prosthesis, Prosthesis User, Prosthetic, Upper Limb Amputation, Upper Limb Amputation Below Elbow, Upper Limb Amputation Below Elbow (Injury)
Interventions: Condition A: Electrode Configuration, Condition B: Electrode Configuration, Condition C: Electrode Configuration, Condition D: Electrode Configuration; Device
Lead sponsor: Liberating Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Holliston, Massachusetts

Conditions: Postoperative Pain, Ventral Hernia, Ventral Hernia Repair
Interventions: Acetaminophen, Bupivicaine, Cyclobenzaprine, Fentanyl, Gabapentin, Hydromorphone, Ketorolac, Thoracic epidural analgesia, Tramadol, magnesium sulfate, transversus abdominis plane block; Drug · Device · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Obstructive Sleep Apnoea, Overweight
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more

Conditions: Schizophrenia
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 32
States / cities: Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 28 more

Search by objective public record fields.

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Resilience-Building for Advance Care Planning

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

COPD Resources, Education, and Activity Designed for You Study

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Does Ethyl Chloride Spray Work?

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Optimize Pattern Recognition Control of Powered Upper Limb Prosthesis

Epidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

A Study of Brenipatide in Adult Participants With Schizophrenia